Blood test hope for liver cancer diagnosis
NCT ID NCT02928627
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether two tiny molecules, called miR-221 and miR-222, can be found in the blood of people with liver cancer. Researchers wanted to see if these molecules could help diagnose the disease without needing a liver biopsy. The study was very small, with only 10 patients, and was terminated early, so the results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could point toward a simple blood test to help diagnose or monitor liver cancer without needing a biopsy.
- What could go wrong
- This was a very small pilot study (only 10 participants) that was terminated early, so results are limited and may not be reliable. It is far from being a proven diagnostic tool.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fiammetta Soggiu
Aberdeen, AB25 2ZN, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?